Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Expert Rev Clin Immunol. 2018 Apr 19;14(5):389–404. doi: 10.1080/1744666X.2018.1463159

Figure 1.

Figure 1

Overview of cGVHD biomarkers workflow from discovery to validation studies.

Biorepositories of cGVHD patients are used to select cases and controls samples matched at similar time points post-HSCT for the discovery of candidate cGVHD biomarkers. Analytical assays are validated by assessing their accuracy, robustness and cost-effectiveness. Validated assays will move forward for validation in large cGVHD cohorts. Last, after approval from the Food and Drug Administration, tests are used in standard practice in cGVHD clinics.